Skip to main content
. 2022 May 26;9:895699. doi: 10.3389/fmed.2022.895699

Figure 2.

Figure 2

Skin biopsy of the scalp findings before (A–C) and 1 year after ruxolitinib treatment began (D–F). Hematoxylin and eosin stains (A,D; ×200) and immunohistochemical stains for CD4 (B,E; ×200) and CD8 (C,F; ×200) showed that infiltrative CD8-positive T cells disappeared after treatment.